The small molecule drug developer, co-founded by a UCLA associate professor, has completed its series B round.

Octant Bio, a US-based small molecule therapeutics developer co-founded by Sri Kosuri, an associate professor at University of California, Los Angeles (UCLA), has secured $80m in its series B round.

Life sciences investment firm Catalio Capital Management led the round, which also featured pharmaceutical firm Bristol Myers Squibb (BMS), boutique investment bank Allen & Company and venture capital firms 50 Years VC and Andreessen Horowitz, the latter through its Bio Fund.

Octant has developed a drug development technology platform that combines…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.